Ocata Therapeutics Inc fka OCAT

[rocky301]

rumit,

I am with you, it seems very confusing. Not long ago Caldwell stated iPS was a science project. Then the report from ACT that iPS cells showed early aging and the hesc's were the route to go. It has been a mixed message from my standpoint. The o-negative "start" seems to be the key. Here are some links that may help or just confuse.

FEB 2010 BioWorld
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46624354

My follow up to article
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46625633

"The firm had a solicitation at the Department of Defense for $5.6 million to create universal blood, but none of the Bush lines were O negative, and ACT was unable to get the White House to sign off on permitting the use of the company's single blastomere technique."
http://investorshub.advfn.com/boards/read_msg.aspx
message_id=46950661